Browsing by Author "Kemal, Y"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Karyotypic study on Silene, section Lasiostemones species from Turkey
    Kemal, Y; Minareci, E; Çirpici, A
    Karyology of the eight taxa of section Lasiostemones from Turkey was investigated. Diploid chromosome numbers and the basic chromosome number of the studied taxa were obtained as 2n=24 and x=12 respectively. The karyotype analysis of studied taxa was carried out and chromosome number of S. capitellata, S. lasiantha and S. manissadjianii were determined at the first time. The largest chromosomes were observed in S. capitellala and the smallest ones were observed in S. isaurica. S. capitellata shows the highest A, index. S. olympica represents the highest interchromosomal asymmetry coefficient (A(2)). The karyologic results of the study and the analysis of chromosomal morphology of each taxon were shown as tables.
  • No Thumbnail Available
    Item
    Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
    Gürbüz, M; Kutlu, Y; Akkus, E; Köksoy, EB; Köse, N; Öven, BB; Uluç, BO; Demiray, AG; Erdem, D; Demir, B; Turhal, NS; Üskent, N; Akbas, S; Selçukbiricik, F; Inal, A; Bilici, A; Ölmez, ÖF; Çabuk, D; Ünal, Ç; Hizal, M; Sendur, MAN; Korkmaz, M; Karadurmus, N; Ertürk, I; Göksu, SS; Tatli, AM; Güven, DC; Kiliçkap, S; Paksoy, N; Aydiner, A; Çinkir, HY; Özkul, Ö; Öztürk, A; Balli, S; Kemal, Y; Erdogan, AP; Er, Ö; Yumuk, PF; Demirkazik, A
    Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.
  • No Thumbnail Available
    Item
    The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
    Yildirim, HÇ; Kutlu, Y; Mutlu, E; Aykan, MB; Korkmaz, M; Yalçin, S; Sakalar, T; Celayir, ÖM; Kayikçioglu, E; Aslan, F; Hafizoglu, E; Altintas, YE; Keskinkiliç, M; Chalabiyev, E; Çelebi, A; Dursun, B; Kapar, C; Özen, M; Acar, O; Dülgar,Ö; Kut, E; Biter, S; Kus, F; Almuradova, E; Erdogan, AP; Saray, S; Güven, DC; Simsek, ET; Üskent, N; Kemal, Y; Çakar, B; Acikgöz,Ö; Kiliçkap, S; Aksoy, S
    IntroductionMale breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients.We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer.IntroductionMale breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients.We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer.MethodsThis study is a multicenter, retrospective study. We included male patients with HR + and HER2-metastatic breast cancer who received palbociclib or ribociclib as first-line treatment. Our primary endpoints were progression-free survival (PFS), overall response rates (ORR), and drug-related adverse effects.ResultsA total of 46 male patients from 27 institutions were enrolled. The median age at initiation of CDK 4/6 inhibitors was 63.64 +/- 13.69 years, with a median follow-up of 21.33 (95% CI 14.92-27.74) months. The ORR were 84% for palbociclib and 76.2% for ribociclib. The mPFS for the entire cohort was 28.06 months (95% CI 18.70-37.42). No significant difference in PFS was observed between palbociclib and ribociclib (mPFS: 24.46 months (95% CI 11.51-37.42) vs 28.33 months (95% CI 14.77-41.88), respectively, p = 0.211). No new adverse events were reported.DiscussionThis study demonstrates that palbociclib and ribociclib are effective and safe options for first-line treatment in male patients with HR + /HER2 - metastatic breast cancer. However, further prospective studies are warranted to establish their efficacy in this population.